- Raised $6M funding round led by Brainsway, Mar 2026
- Raised $5M funding round led by Brainsway, Aug 2025
- Raised $4.8M funding round, Jun 2017
About
Neurolief develops treatments for patients with chronic neurological and neuropsychiatric disorders. The company has created a digital therapeutics platform of clinically proven neuromodulation-based solutions that can be delivered to patients at home or in the community. Neuroliefs Relivion is a noninvasive multichannel brain neuromodulation system for treating neurological and neuropsychiatric disorders. It offers precise, personalized care by delivering stimulation to six branches of the occipital and trigeminal nerves via three adaptive output channels. This creates a cumulative effect by releasing neurotransmitters in the brainstem to modulate the brain networks associated with pain and mood control. The Relivion device is placed comfortably on the patients head, where it stimulates the nerves. The connected e-Relief mobile app displays the treatment status and transmits information between the patient and the cloud. The Relivion system is FDA approved and CE marked and has been granted breakthrough device designation by the FDA.
Funding history · 4 rounds · $17.1M total
Q&A
- What is Neurolief's primary focus?
- Neurolief develops treatments for patients with chronic neurological and neuropsychiatric disorders, utilizing a digital therapeutics platform of neuromodulation-based solutions.
- What is Neurolief's flagship product?
- Neurolief's flagship product is Relivion, a noninvasive multichannel brain neuromodulation system designed for treating neurological and neuropsychiatric disorders.
- What is the regulatory status of the Relivion system?
- The Relivion system is FDA approved and CE marked, and has also been granted breakthrough device designation by the FDA.
- When was Neurolief founded?
- Neurolief was founded in August 2013.
- How many employees does Neurolief currently have?
- Neurolief has 11-50 employees.
- What was Neurolief's most recent funding round?
- Neurolief closed a funding round in March 2026, with Brainsway as a lead investor.
- What was Neurolief's second most recent funding round?
- Neurolief closed a funding round in August 2025, with Brainsway as a lead investor.
- What is the total amount of funding Neurolief has raised to date?
- Neurolief has raised a total of $17,050,000 USD.
- Which sectors does Neurolief operate in?
- Neurolief operates in Health Tech & Life Sciences, Digital Healthcare, and Digital Therapeutics sectors.
Team · 2
Sectors & technology
Highlights
Tags
Full data — links, identifiers, deals & radar signals (jobs, patents, research, more)
External links
| Website | prolivrx.com |
|---|---|
| linkedin.com/company/11692471 | |
| YouTube | youtube.com/channel/UCLXRI7aEbPOcvFKNtvkmf2Q |
Identifiers & details
| Founded | 2013-8 |
|---|---|
| Employees (exact) | 28 |
| Offices | Tampa |
Radar intelligence
Patents
| EPO | 8 |
|---|
Web history (Wayback)
| Domain | prolivrx.com |
|---|
Certificate / subdomain footprint
| Subdomains | 2 |
|---|